Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

cps 2

Drug Profile

cps 2

Alternative Names: rA2cp248/404-1030 Delta SH genetically stabilised; Recombinant live-attenuated respiratory syncytial virus vaccine - Medimmune/NIAID; Respiratory syncytial virus vaccine cps2; RSV vaccine live-attenuated genetically stabilised - Medimmune/NIAID

Latest Information Update: 28 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In infants, Prevention) in USA (Intranasal, Drops)
  • 01 Sep 2013 Phase-I clinical trials in Respiratory syncytial virus infections (prevention in infants) in USA (Intranasal)
  • 01 Sep 2013 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for Respiratory syncytial virus infections (prevention) in USA (NCT01968083)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top